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Stimulation (SCS) provides pain relief and improves patients’ health. We 
assessed in a naturalistic context the cost-utility of SCS in FBSS patients 
unresponsive to conventional medical management (CMM). METHODS: We 
conducted an observational, multicenter, longitudinal prospective study in 
which a sample of patients assigned to receive SCS in addition to CMM was 
observed for 24 months after the intervention. We collected before and after 
undergoing SCS the following data: direct and indirect costs, adopting the 
National Health Service (NHS) and the societal perspectives, pain status, using 
the Numerical Rating Scale (NRS, scoring from 0 (no pain) to 10 (maximum pain)), 
and HRQoL, using the SF-36 and EQ-5D. Costs and benefits pre-SCS versus post-
SCS were compared to estimate the incremental cost-effectiveness and the cost-
utility ratios. The following results focus on the cost/QALY ratio. RESULTS: 
Eighty patients (40% male, mean age 58 years) were recruited. Significant 
improvements in pain intensity and HRQoL were reached after 6 months from 
SCS and maintained or further improved until the end of the observational 
period. In particular, after 24 months from SCS the mean NRS significantly 
decreased (p<0.01) from 7.6 to 5.1, and the mean EQ-5D-utility significantly 
(p<0.01) increased from 0.07 to 0.40. The ICUR was equal to 27,519€/QALY, 
according to the NHS perspective. The cost-utility acceptability curve shows that 
if decision makers’ willingness-to-pay per QALY was 45,000€, then SCS 
implantation would be cost effective in 97% and 99% of cases, according to the 
societal and NHS perspectives, respectively. CONCLUSIONS: In a 2-year 
observational period, SCS+CMM treatment of FBSS patients increases medical 
direct costs but allows to improve significantly patients’ clinical health and 
HRQoL, resulting in a cost/QALY ratio largely lower than the commonly accepted 
willingness-to-pay threshold.  
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OBJECTIVES: Under the standard methods of health technology assessment 
(HTA) incorporating economic evaluation, orphan drugs do not usually prove to 
be cost-effective. Adding their high cost, it meant that funding and patient 
access may be limited in the Brazilian Public Health System (SUS). Acromegaly is 
one example, with annual incidence of 3-4 cases/million and prevalence of 40-90 
cases/million. There is a new drug, pegvisomant, which presents a relative 
efficacy at a high cost. With the objective to identify the best 
pharmacoeconomics evidence for pegvisomant in acromegaly and to review the 
knowledgment transfer to support a rapid economic review of rare diseases 
under the perspective of SUS. METHODS: In the case of the rare disease 
acromegaly a search was conducted on February 10th, 2013 using \’cost\’/exp OR 
cost AND effectiveness AND (\’pegvisomant\’/exp OR pegvisomant) AND 
(\’acromegaly\’/exp OR acromegaly) in Medline (PubMed), EMBASE, Virtual Health 
Library (BVS), Center for Reviews and Dissemination (CRD), The Cochrane 
Library. RESULTS: Only the study “Clinical effectiveness and cost-effectiveness of 
pegvisomant for the treatment of acromegaly: a systematic review and economic 
evaluation” was identified and selected. The study was conducted in the UK, 
where health costs are different from the Brazilian structure RESULTS: The 
study´s evidence indicates that pegvisomant is not cost-effective to treat 
pacients with resistant agromegaly. In Brazil the cost of each dose in the public 
health system is about 25% more expensive than the UK, and so is the cost of 
labor. CONCLUSIONS: The need of economic assessment transferability as a tool 
to support the management of political decisions, especially to high cost 
technologies and rare diseases, are not set as priority in the research fostering 
agenda of the SUS  
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OBJECTIVES: Type I Gaucher disease (GD) is an autosomal recessive disorder 
caused by a deficiency in β-glucocerebrosidase enzyme, causing 
hepatosplenomegaly, anaemia, trombocitopenia, bone injuries and other 
complications. Intravenous enzyme replacement therapy (ERT) is the current 
standard of care, which has demonstrated in several studies its efficacy in  
the prevention and amelioration of progressive and systemic manifestations. 
Velaglucerase alpha is a glycoprotein with the same amino acid sequence as the 
human enzyme β-glucocerebrosidase. The aim of this study is to assess the cost-
effectiveness of velaglucerase alpha versus imiglucerase for the treatment  
of type 1 GD from the perspective of the Spanish National Healthcare System 
(NHS). METHODS: A cost-utility analysis was performed using a semi-Markov 
model that embedded one decision tree for the initial treatment during two 
years and a Markov health state structure after the response to the second year 
receiving ERT, from the NHS perspective. The Markov framework was structured 
around six health states: asymptomatic, mild, moderate, severe, splenectomy 
and death and used annual cycles with a time horizon of 39 years. Model 
structure was validated by a panel of GD experts. Efficacy data were obtained 
from the HGT-GCB-039 study. Resources consumption was based on expert 
opinion. Outcomes were quality-adjusted life years (QALY) and costs (€ in 2011). 
Threshold sensitivity analysis was conducted to determine cost-neutrality 
between strategies. RESULTS: Both strategies provided a mean gained of 25.55 
QALYs. The average cost per patient for velaglucerase alpha was €7,265,332 
compared to €7,327,966 for imiglucerase. The difference in costs was mainly due 
to the difference in administration costs. The threshold sensitivity analysis 
showed that velaglucerase alpha will reach cost-neutrality even with a higher 
unit price. CONCLUSIONS: Velaglucerase alpha is a cost-saving option for the 
treatment of type 1 GD in the Spanish setting, providing annual savings 
compared with imiglucerase. (This study was supported by Shire 
Pharmaceuticals Iberica)  
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OBJECTIVES: The purpose of this study was to conduct an economic analysis  
of clinical effectiveness of antiviral drugs in monotherapy (entecavir, 
lamivudine, telbivudine, tenofovir, peginterferon alfa-2a) compared with  
no specific treatment for patients with chronic hepatitis B in Russia. METHODS: 
Clinical-economic study was carried out with the Markov model.The duration of 
one cycle-1 year,the duration of antiviral treatment-5 years.As a measure  
of utility QALY were used. Due to the absence of Russian studies, a multinational 
study from 2008 was used. RESULTS: Total cost of one year of treatment  
of chronic hepatitis B were: lamivudine-35732.97 rubles, for entecavir-96104.00 
rubles for tenofovir-103279.55,for telbivudine-116933.75 for peginterferon-alfa-
2a-502238.40 rubles. The lowest cost-utility ratio (CUR) was for lamivudine-
91159.54 rubles/QALY. The highest CUR is for pegylated interferon alfa-2a and 
then tenofovir/entecavir-183263.00 rubles/QALY and 176936.58 rubles/QALY, 
respectively. More cost-effective treatment is to start with the third- 
line drugs-entecavir/tenofovir. The study showed that the use of 
entecavir,lamivudine,tenofovir is clinically and economically more effective than 
using no specific antiviral therapy.The CURs for these tactics is lower than that 
for the natural course of the disease.More effective from a clinical and economic 
point of view, for the treatment of chronic hepatitis B is to use as single one  
of these:entecavir/tenofovir/lamivudine. CONCLUSIONS: The quality of life  
of patients with chronic hepatitis B without the specific treatment will be lower 
than that with the antiviral drugs,since without the treatment increases the  
rate of formation of severe fibrosis in the liver, there is a quicker outcome to 
cirrhosis and other complications.Lowest CUR is for lamivudine due to the low 
cost of it,but the high rate of resistance to lamivudine and the need to add  
additional third-generation drug may increase the cost.The highest  
CUR is with administering pegylated interferon-alfa-2a and then  
applying tenofovir/entecavir. It seems economically feasible to begin therapy 
immediately with the administration of the third generation drug - entecavir or 
tenofovir.  
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OBJECTIVES: Few studies have reported the impact of laparoscopic adjustable 
gastric banding (LAGB) on work productivity in obese patients. The objective of 
this HERO study analysis is to examine the effect of weight loss (WL) on work 
productivity (absenteeism, presenteeism, and productivity loss) and non-work 
activity impairment 1 year (yr) after laparoscopic placement of LAP-BAND AP® 
System. METHODS: HERO is a 5-yr registry of 1,106 obese patients from 29 
centers in the United States (US), Canada, Europe, and Australia who underwent 
LAGB. Our descriptive analysis included about 70% of subjects who provided 
complete baseline (BL) and 1 yr health related quality of life data based on Work 
Productivity and Activity Impairment questionnaire, a well validated instrument 
generating scores in absenteeism, presenteeism, work productivity loss and non-
work activity impairment. RESULTS: The mean age was 43.1 yrs and females 
constituted 79.3%. At BL, 59% worked full time and 10% worked part time. Mean 
(SD) baseline weight was 126.2 (24.14) kg. At 1 year, the average %WL was 16.9% 
(SD, 9.02). Baseline presenteeism was 4.5%, absenteeism 33.4%, work productivity 
3.8%, and non-work activity impairment was 51.2%. At 1 year, there was 
reduction in presenteeism to 2.8% (p<0.05), in absenteeism to 20% (p<0.05), in 
work productivity to 2.3% (p<0.05), and non-work activity impairment to 28% 
(p<0.05). There was a decreasing trend in presenteeism (23.4%, 20.4%, 18.2%, 
14.1%, p=0.01) and less non-work activity impairment (32.9%, 29.7%, 22.7%, 17.5%, 
p<0.001) as %WL increased from 0-10%, to >10-20%, to >20-30%, and to >30%. 
This decrease was not observed with absenteeism (1.9%, 3.8%, 2.5%, 1.7%, p=0.28) 
nor productivity loss (2.1%, 2.2%, 2.7%, 1.8%, p=0.74) as %WL increased. 
CONCLUSIONS: LAGB was associated with significant WL and improvement in 
work productivity and reduction in non-work activity impairment by 1 yr. 
Further analysis will examine the sustainability of WL effect on impact on work 
productivity.  
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